

# Melissa A Prah

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2287059/publications.pdf>

Version: 2024-02-01

25  
papers

582  
citations

759233

12  
h-index

839539

18  
g-index

25  
all docs

25  
docs citations

25  
times ranked

973  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 1745-1758.	3.4	11
2	Basal Ganglia Iron Content Increases with Glioma Severity Using Quantitative Susceptibility Mapping: A Potential Biomarker of Tumor Severity. <i>Tomography</i> , 2022, 8, 789-797.	1.8	5
3	Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial. <i>Neuro-Oncology</i> , 2021, 23, 314-323.	1.2	18
4	Magnetic Resonance Imaging Mapping of Brain Tumor Burden: Clinical Implications for Neurosurgical Management: Case Report. <i>Neurosurgery Open</i> , 2021, 2, okab029.	0.2	5
5	Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 979-986.	0.8	14
6	Evaluating the Use of rCBV as a Tumor Grade and Treatment Response Classifier Across NCI Quantitative Imaging Network Sites: Part II of the DSC-MRI Digital Reference Object (DRO) Challenge. <i>Tomography</i> , 2020, 6, 203-208.	1.8	12
7	TMOD-25. IN VIVO MODEL OF TREATMENT-RESISTANT GLIOBLASTOMA HIGHLIGHTS SEX DIFFERENCES IN SURVIVAL. <i>Neuro-Oncology</i> , 2020, 22, ii233-ii233.	1.2	0
8	THER-12. NOVEL IRON-TARGETED THERAPY IS HIGHLY EFFECTIVE IN TREATMENT-RESISTANT HIGH-GRADE GLIOMA IN VIVO. <i>Neuro-Oncology</i> , 2019, 21, ii116-ii116.	1.2	0
9	Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors. <i>American Journal of Neuroradiology</i> , 2019, 40, 626-633.	2.4	30
10	Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. <i>American Journal of Neuroradiology</i> , 2019, 40, 1132-1139.	2.4	19
11	NIMG-28. VALIDATION OF SINGLE-DOSE DSC-MRI PROTOCOLS FOR ROBUST PERFUSION ASSESSMENT IN BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019, 21, vi167-vi167.	1.2	0
12	Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO). <i>Tomography</i> , 2019, 5, 110-117.	1.8	25
13	Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics. <i>Journal of Neuro-Oncology</i> , 2018, 136, 13-21.	2.9	37
14	EXTH-48. ORAL GALLIUM MALTOLATE IMPAIRS TUMOR GROWTH AND EXTENDS DISEASE-SPECIFIC SURVIVAL IN A XENOGRAFT MODEL OF RECURRENT GBM. <i>Neuro-Oncology</i> , 2018, 20, vi95-vi95.	1.2	0
15	Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project. <i>American Journal of Neuroradiology</i> , 2018, 39, 1008-1016.	2.4	43
16	ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. <i>PLoS ONE</i> , 2018, 13, e0198548.	2.5	21
17	Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. <i>Journal of Medical Imaging</i> , 2017, 5, 1.	1.5	22
18	Toward uniform implementation of parametric map Digital Imaging and Communication in Medicine standard in multisite quantitative diffusion imaging studies. <i>Journal of Medical Imaging</i> , 2017, 5, 1.	1.5	5

#	ARTICLE	IF	CITATIONS
19	ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. <i>Clinical Cancer Research</i> , 2016, 22, 5079-5086.	7.0	99
20	NIMG-58PRELIMINARY TRENDS IN ADVANCED IMAGING RELATIVE TO STANDARD IMAGING IN SUBJECTS TREATED WITH OPTUNE. <i>Neuro-Oncology</i> , 2015, 17, v167.2-v167.	1.2	0
21	NIMG-01ADVANCED MR PERFUSION AND DIFFUSION MEASURES DISTINGUISH BETWEEN GLIOMA SUBTYPES. <i>Neuro-Oncology</i> , 2015, 17, v153.1-v153.	1.2	0
22	Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. <i>Neuro-Oncology</i> , 2015, 17, 1148-1156.	1.2	108
23	ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2024-2024.	1.6	1
24	Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. <i>Neuro-Oncology</i> , 2014, 16, 880-888.	1.2	107
25	NI-03 * DSC-MRI MEASURES OF rCBV PREDICT TUMOR CHARACTERISTICS BEYOND STANDARD HISTOPATHOLOGY. <i>Neuro-Oncology</i> , 2014, 16, v138-v138.	1.2	0